Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News | New Ways for Purging the HIV ReservoirA number of different methods are being looked at to deal with the HIV reservoirs, and the majority of the most recent clinical trials are studying the effectiveness of HDAC inhibitors.
By: Alain Lafeuillade Even with highly active antiretroviral therapy (HAART), it would take more than 70 years to completely decay the HIV reservoirs, making full eradication practically impossible. Therefore, eliminating the reservoirs has to be done without spreading the infection to unharmed cells. The most ideal situation is to somehow purge the HIV reservoirs without activating T-cells, which could leave them susceptible to infection. Histone deacetylase (HDAC) inhibitors have interesting effects, and current studies have hypothesized that HDAC inhibitors may target the dormant HIV reservoirs, possibly getting rid of the virus without the entire body's supply of T-cells activating. But which HDAC inhibitor can we use in order to achieve this effect? There are three general types of HDAC: Class I, Class II, and Class-111. Studies have suggested that Class I HDAC inhibitors might be the best choice, but other avenues are currently being explored. Trials with valproic acid (VPA), an HDAC inhibitor that is often prescribed to epileptic patients, showed a significant reduction in HIV reservoir size in 3 out of four patients when VPA was added to the HAART regimen. Vorinostat, Givinostat, Belinostat, three prominent HDAC inhibitors, even produced better results in vitro. A number of different methods are being looked at to deal with the HIV reservoirs, and the majority of the most recent clinical trials are studying the effectiveness of HDAC inhibitors. The goal is to significantly reduce or eliminate the HIV reservoir. Time will tell if researchers ultimately come up with the right combination of drugs and treatment to build a cure, and whether that cure winds up being a functional one or a sterilizing one, it's worth mentioning that important progress has already been made. Media Contact: Alain Lafeuillade AVPS 1208 Avenue Colonel Picot 83056 Toulon France 33-4-94616340 lafeuillade@ http://www.towards- End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|